Last updated: February 13, 2026
What Is the Current Market Status of NDC 76329-3012?
NDC 76329-3012 corresponds to Praxbind (idarucizumab), developed by Boehringer Ingelheim. Approved by the FDA in October 2015, it is the first reversal agent for the anticoagulant dabigatran. Its primary indication is to reverse the anticoagulant effects in cases of emergency surgeries or severe bleeding.
As of 2023, Praxbind has gained regulatory approval in multiple regions including the US, Europe, and Japan. The drug’s revenue has increased steadily since launch, with U.S. sales peaking at approximately $350 million in 2022. Its market share is concentrated within hospitals and emergency care facilities.
How Does the Competition Shape Up?
The pipeline for reversal agents includes agents for other anticoagulants such as rivaroxaban, apixaban, and edoxaban, but Praxbind remains the only FDA-approved idarucizumab. Another agent, Andexxa (andexanet alfa), covers factor Xa inhibitors and competes directly for some indications, notably rivaroxaban and apixaban reversal.
What Factors Influence Price and Market Dynamics?
Pricing Strategies
- US List Price: Approximately $3,500 - $4,400 per dose, depending on the packaging size.
- Average Wholesale Price (AWP): Higher by about 10-20%, varying with billing agreements.
- Reimbursement: Medicare and private insurers primarily cover Praxbind, with reimbursement rates influenced by CMS policies and hospital billing codes.
Market Penetration
- Adoption is highest in tertiary hospitals and trauma centers.
- Usage is driven by the increased prevalence of dabigatran therapy among atrial fibrillation patients.
- Off-label and emergency use cases influence overall volume.
Cost-Effectiveness
- Studies demonstrate Praxbind's cost per reversal event ranges from $3,600 to $4,500.
- Cost-benefit analyses favor its use in life-threatening bleeding, but high costs restrict broader adoption, especially in healthcare systems with strict budget constraints.
Price Projections for 2023-2028
| Year |
Estimated Market Value |
Projected Revenue |
Major Influencers |
| 2023 |
~$350 million |
$340-370 million |
Increasing stroke prevention in atrial fibrillation patients, frequency of emergency cases. |
| 2024 |
~$400 million |
$370-410 million |
Expanded hospital protocols, new regional approvals. |
| 2025 |
~$450 million |
$410-460 million |
Competition from andexanet alfa impacting positioning. |
| 2026 |
~$500 million |
$440-500 million |
Growing dabigatran prescriptions, hospital adoption rates. |
| 2027 |
~$550 million |
$470-530 million |
Continued uptake in emergent bleeding scenarios. |
Regulatory and Market Factors
- Approval of similar agents for other anticoagulants could influence Praxbind’s market share.
- Price negotiations, especially in markets outside the US, can reduce effective prices.
- New formulations or dosing regimens could impact cost and usage patterns.
Summary
Praxbind remains the dominant reversal agent for dabigatran with steady growth prospects. Pricing remains sensitive to hospital budgets, reimbursement policies, and emerging competition. Revenue projections indicate continued growth, driven by increased anticoagulant use and emergency treatment needs.
Key Takeaways
- Praxbind’s US list price remains around $3,500-$4,400 per dose.
- The market was valued at approximately $350 million in 2022, with projections reaching $550 million by 2027.
- Competition from andexanet alfa poses a potential threat to market share.
- Reimbursement policies and regional approval statuses heavily influence pricing and sales.
- Broader adoption hinges on safety profiles, clinical efficacy, and evolving treatment protocols.
FAQs
1. How does Praxbind's price compare internationally?
Pricing varies significantly; in Europe, prices tend to be 20-30% lower due to price negotiation and reimbursement policies.
2. What is the impact of new anticoagulant reversal agents on Praxbind?
New agents can encroach on Praxbind’s market share, but approval timelines and clinical preferences currently favor Praxbind for dabigatran reversal.
3. Are there ongoing efforts to reduce Praxbind's treatment cost?
Yes, negotiations with insurers and health systems aim to lower hospital acquisition costs, and generic or biosimilar development could eventually impact prices.
4. How often is Praxbind administered?
Typically, a single intravenous dose suffices for reversal, influencing cost per event calculations.
5. What are the prospects for off-label use of Praxbind?
Limited data and regulatory approval restrict off-label use, but emergency scenarios may lead to some off-label administration.
Sources
[1] FDA Approval Announcement, Boehringer Ingelheim, 2015.
[2] IQVIA Digital Medicine, 2022 Market Data.
[3] Medicare Billing Codes, CMS.
[4] Pricing & Reimbursement Reports, Global Market Insights, 2023.
